Clearmind Medicine files international patent application under PCT

Clearmind Medicine announced the filing of a new international patent application under the Patent Cooperation Treaty, PCT. The application covers its innovative combination therapy of MEAI and Palmitoylethanolamide, PEA. This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease. The Company believes that its novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This patent filing is part of Clearmind’s ongoing collaboration with SciSparc, a clinical-stage specialty pharmaceutical company developing therapies for central nervous system disorders.